Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

HHS Logo Eagle IconU.S. Department of Health and Human Services

Office of Science and Data Policy (SDP)

The Office of Science and Data Policy is the departmental focal point for policy research, analysis, evaluation, and coordination of department-wide public health science policy and data policy activities and issues. The Office provides authoritative advice and analytical support to the ASPE and departmental leadership on public health science policy and data policy issues and initiatives, coordinates science and data policy issues of interagency scope within HHS, and manages interagency initiatives in science policy and data policy. The Office works closely with staff from across the Department on strategic plan development and implementation efforts. The Offices also carries out a program of policy research, analysis, evaluation, and data development in these issues.

The Office of Science and Data Policy includes several components:

Topic Areas:

  • HHS Data Council
  • Regulatory Impact Analysis
  • Strategic Planning
  • Information Quality Guidelines
  • Prevention and wellness
  • Public health systems and functions
  • Food safety and nutrition
  • Drugs and devices
  • Tobacco control and prevention
  • Biomedical research and development
  • Economic analysis
  • Emergency preparedness, response, and recovery
  • Data and statistical policy
  • Health disparities and vulnerable populations
  • Health information technology
  • Microsimulation
  • Privacy policy

Reports

Displaying 51 - 60 of 161. 10 per page. Page 6.

Advanced Search
Report

Addressing Uncertainty in Regulatory Impact Analysis

In 2016, the U.S. Department of Health and Human Services finalized its Guidelines for Regulatory Impact Analysis under the leadership of its Assistant Secretary for Planning Evaluation and Analytics Team. The Guidelines discuss strategies for characterizing the uncertainty in quantified effects as well as the potential impacts of non-quantified effects.
Report

Prescription Drug Supply Chains: An Overview of Stakeholders and Relationships

Many stakeholders and steps are involved in the life cycle of a prescription drug as it moves from chemical synthesis and formulation through dispensing or administration to patients. The specific steps involved in prescription drug supply chains often differ depending on the type of drug, the channel of distribution, and the patient’s source of prescription drug coverage.
Report

Medical Device Supply Chains: An Overview and Description of Challenges During the COVID-19 Pandemic

This report provides an introduction to the supply chain for COVID-19 relevant medical devices and related challenges faced in ramping up their production during the COVID-19 pandemic.
Report

Assessing Relationships between Drug Shortages in the United States and Other Countries

Drug shortages are a persistent public health problem in the United States and in other countries. Shortages can have important implications for the health care systems and pharmacies that purchase, store, and dispense drugs and for the patients who rely on the availability of drugs to treat and prevent disease.
Research Brief

Drug Checking Programs in the United States and Internationally: Environmental Scan Summary

This environmental scan presents a review and synthesis of approaches and strategies adopted by drug checking programs and existing evidence on their effectiveness in changing drug use attitudes, behavior, and health outcomes. It includes studies of drug checking programs across a variety of settings in the United States and internationally.
Report

Guidelines for Regulatory Impact Analysis Supplement: Addressing International Effects

This report extends the brief discussion of addressing international effects contained in the Department of Health and Human Service Guidelines for Regulatory Impact Analysis (2016). The purpose of this supplement is to expand that discussion and provide more detailed information on conducting such assessments. Related Products:
ASPE Issue Brief

Parents' Intentions to Vaccinate Children Ages 12-17 for COVID-19: Demographic Factors, Geographic Patterns, and Reasons for Hesitancy

As of September 13, 2021, three vaccines to prevent infection with SARS-CoV-2, the virus that causes COVID-19, are available in the United States. The Pfizer vaccine was granted full approval for use in individuals over the age of 16 by the U.S.
ASPE Issue Brief

Trends in Antimicrobial Drug Prescribing During the COVID-19 Pandemic

COVID-19 has impacted antimicrobial drug prescribing both directly, through COVID-19 treatment, and indirectly, through the reduced spread of illnesses for which antimicrobial drugs are commonly prescribed.
Report

Comprehensive Plan for Addressing High Drug Prices: A Report in Response to the Executive Order on Competition in the American Economy

President Biden’s Executive Order 14036, “Promoting Competition in the American Economy” (the Competition Executive Order), identifies a lack of competition as a key driver for problems across economic sectors.
ASPE Issue Brief

The Impact of the COVID-19 Pandemic on Major HHS Data Systems

The COVID-19 pandemic and policy responses, including stay-at-home orders and expanded use of telework, disrupted data collection for major HHS data systems. This brief identifies the impact of the pandemic on 29 HHS statistical surveys and administrative data systems widely used by policymakers and the public.